Download PDF
J Neurol Surg B Skull Base
DOI: 10.1055/a-2226-8414
Original Article

Induction Chemotherapy for Locoregionally Advanced Sinonasal Squamous Cell Carcinoma

Arash Abiri 
1   Department of Otolaryngology–Head and Neck Surgery, University of California, Irvine, Orange, California, United States
,
Derek H. Liu
1   Department of Otolaryngology–Head and Neck Surgery, University of California, Irvine, Orange, California, United States
,
Theodore V. Nguyen
1   Department of Otolaryngology–Head and Neck Surgery, University of California, Irvine, Orange, California, United States
,
Jonathan C. Pang 
1   Department of Otolaryngology–Head and Neck Surgery, University of California, Irvine, Orange, California, United States
,
Sina J. Torabi
1   Department of Otolaryngology–Head and Neck Surgery, University of California, Irvine, Orange, California, United States
,
Edward C. Kuan
1   Department of Otolaryngology–Head and Neck Surgery, University of California, Irvine, Orange, California, United States
2   Department of Neurological Surgery, University of California, Irvine, Orange, California, United States
› Author Affiliations Funding This work was supported in part by the National Institute of General Medical Sciences of the National Institutes of Health under award number T32GM008620.
› Further Information
    Permissions and Reprints

Abstract

Background There is emerging evidence to suggest the role of induction chemotherapy (IC) in definitive management of locoregionally advanced sinonasal squamous cell carcinoma (SNSCC). We evaluated the influence of IC on survival and predictors of its use in SNSCC patients.

Methods The 2004 to 2017 National Cancer Database was queried for patients with locoregionally advanced SNSCC (T4/M0). Treatments were stratified into seven groups: definitive chemoradiation (CRT), IC with definitive CRT (IC + CRT), IC + CRT with salvage surgery (IC + CRT + Sx), definitive surgery (Sx), IC with definitive surgery (IC + Sx), definitive surgery with adjuvant radiation or CRT (Sx + ATx), or IC + Sx + ATx. Cox proportional-hazards regression assessed overall survival (OS) and logistic regression identified predictors of IC.

Results Of 3,162 patients, 1,088 (34.4%) were female with a mean age of 63.4 ± 13.4 years. The 2- and 5-year OS rates were 58.6 and 42.0%, respectively. Compared with CRT, Sx + ATx (hazard ratio [HR]: 0.663; p < 0.001), IC + Sx (HR: 0.606; p = 0.005), or IC + Sx + ATx (HR: 0.468; p = 0.001) exhibited reduced mortality. Among patients who were treated with definitive surgery, those receiving IC had additional OS benefit (all ps < 0.05). Older age (odds ratio [OR]: 0.607; p < 0.001), female sex (OR: 0.759; p = 0.028), Black race (OR: 1.650; p < 0.001, T4b stage (OR: 1.674; p < 0.001), and higher N stage (OR: 1.395; p < 0.001) were predictors of IC.

Conclusions IC prior to definitive surgery with or without adjuvant therapy exhibited the highest OS for locoregionally advanced SNSCC. Age, sex, race, and T/N staging were predictors of IC. Multimodal treatment regimens involving surgery as the primary modality may, therefore, provide the greatest therapeutic response.

Keywords

sinonasal carcinoma - neoadjuvant chemotherapy - induction chemotherapy - survival - outcomes research

Previous Presentation

Portions of this work were presented as a talk at the 2023 Triological Society Combined Sections Meeting, Coronado, CA.


Supplementary Material



Publication History

Received: 05 October 2023

Accepted: 07 December 2023

Accepted Manuscript online:
12 December 2023

Article published online:
09 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sanghvi S, Khan MN, Patel NR, Yeldandi S, Baredes S, Eloy JA. Epidemiology of sinonasal squamous cell carcinoma: a comprehensive analysis of 4994 patients. Laryngoscope 2014; 124 (01) 76-83
    CrossrefPubMedGoogle Scholar
  • 2 Elgart K, Faden DL. Sinonasal squamous cell carcinoma: etiology, pathogenesis, and the role of human papilloma virus. Curr Otorhinolaryngol Rep 2020; 8 (02) 111-119
    CrossrefPubMedGoogle Scholar
  • 3 Llorente JL, López F, Suárez C, Hermsen MA. Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol 2014; 11 (08) 460-472
    CrossrefPubMedGoogle Scholar
  • 4 Ferrari M, Taboni S, Carobbio ALC. et al. Sinonasal squamous cell carcinoma, a narrative reappraisal of the current evidence. Cancers (Basel) 2021; 13 (11) 2835
    CrossrefPubMedGoogle Scholar
  • 5 Kılıç S, Kılıç SS, Baredes S. et al. Comparison of endoscopic and open resection of sinonasal squamous cell carcinoma: a propensity score-matched analysis of 652 patients. Int Forum Allergy Rhinol 2018; 8 (03) 421-434
    CrossrefPubMedGoogle Scholar
  • 6 Homma A, Nakamaru Y, Lund VJ. et al. Endonasal endoscopic surgery for sinonasal squamous cell carcinoma from an oncological perspective. Auris Nasus Larynx 2021; 48 (01) 41-49
    CrossrefPubMedGoogle Scholar
  • 7 Abiri A, St John MA, Kuan EC. What is the role of induction chemotherapy in the treatment of locally advanced sinonasal squamous cell carcinoma?. Laryngoscope 2023; 133 (02) 214-215
    CrossrefPubMedGoogle Scholar
  • 8 Khoury T, Jang D, Carrau R, Ready N, Barak I, Hachem RA. Role of induction chemotherapy in sinonasal malignancies: a systematic review. Int Forum Allergy Rhinol 2019; 9 (02) 212-219
    CrossrefPubMedGoogle Scholar
  • 9 National Cancer Database. American College of Surgeons. 2020. Accessed March 1, 2023 at https://www.facs.org/Quality-Programs/Cancer/NCDB
    PubMed
  • 10 Lehrich BM, Goshtasbi K, Abiri A. et al. Impact of induction chemotherapy and socioeconomics on sinonasal undifferentiated carcinoma survival. Int Forum Allergy Rhinol 2020; 10 (05) 679-688
    CrossrefPubMedGoogle Scholar
  • 11 Farrell NF, Mace JC, Detwiller KY. et al. Predictors of survival outcomes in sinonasal squamous cell carcinoma: an analysis of the National Cancer Database. Int Forum Allergy Rhinol 2021; 11 (06) 1001-1011
    CrossrefPubMedGoogle Scholar
  • 12 Yoo W, Mayberry R, Bae S, Singh K, Peter He Q, Lillard Jr JW. A study of effects of multicollinearity in the multivariable analysis. Int J Appl Sci Technol 2014; 4 (05) 9-19
    PubMedGoogle Scholar
  • 13 Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012; 34 (06) 877-885
    CrossrefPubMedGoogle Scholar
  • 14 Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001; 92 (12) 3012-3029
    CrossrefPubMedGoogle Scholar
  • 15 Wang Z, Zhang J, Yang B. et al. T4b sinonasal squamous cell carcinoma: surgery plus radiotherapy may contribute to prolonged survival. Laryngoscope 2023; 133 (09) 2222-2231
    CrossrefPubMedGoogle Scholar
  • 16 Thawani R, Kim MS, Arastu A. et al. The contemporary management of cancers of the sinonasal tract in adults. CA Cancer J Clin 2023; 73 (01) 72-112
    CrossrefPubMedGoogle Scholar
  • 17 Sharma RK, Irace AL, Schlosser RJ. et al. Conditional and overall disease-specific survival in patients with paranasal sinus and nasal cavity cancer: improved outcomes in the endoscopic era. Am J Rhinol Allergy 2022; 36 (01) 57-64
    CrossrefPubMedGoogle Scholar
  • 18 Jafari A, Shen SA, Qualliotine JR, Orosco RK, Califano JA, DeConde AS. Impact of margin status on survival after surgery for sinonasal squamous cell carcinoma. Int Forum Allergy Rhinol 2019; 9 (10) 1205-1211
    CrossrefPubMedGoogle Scholar
  • 19 Robin TP, Jones BL, Gordon OM. et al. A comprehensive comparative analysis of treatment modalities for sinonasal malignancies. Cancer 2017; 123 (16) 3040-3049
    CrossrefPubMedGoogle Scholar
  • 20 Amit M, Abdelmeguid AS, Watcherporn T. et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol 2019; 37 (06) 504-512
    CrossrefPubMedGoogle Scholar
  • 21 Murr AT, Lenze NR, Weiss JM. et al. Sinonasal squamous cell carcinoma survival outcomes following induction chemotherapy vs standard of care therapy. Otolaryngol Head Neck Surg 2022; 167 (05) 846-851
    CrossrefPubMedGoogle Scholar
  • 22 Hanna EY, Cardenas AD, DeMonte F. et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg 2011; 137 (01) 78-81
    CrossrefPubMedGoogle Scholar
  • 23 Ock CY, Keam B, Kim TM. et al. Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. Korean J Intern Med (Korean Assoc Intern Med) 2016; 31 (03) 570-578
    PubMedGoogle Scholar
  • 24 Abdelmeguid AS, Teeramatwanich W, Roberts DB. et al. Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer 2021; 127 (11) 1788-1795
    CrossrefPubMedGoogle Scholar
  • 25 Hirakawa H, Hanai N, Ozawa T. et al. Prognostic impact of pathological response to neoadjuvant chemotherapy followed by definitive surgery in sinonasal squamous cell carcinoma. Head Neck 2016; 38 (Suppl. 01) E1305-E1311
    CrossrefPubMedGoogle Scholar
  • 26 Kim GE, Chang SK, Lee SW. et al. Neoadjuvant chemotherapy and radiation for inoperable carcinoma of the maxillary antrum: a matched-control study. Am J Clin Oncol 2000; 23 (03) 301-308
    CrossrefPubMedGoogle Scholar
  • 27 Vartanian JG, Toledo RN, Bueno T, Kowalski LP. Orbital exenteration for sinonasal malignancies: indications, rehabilitation and oncologic outcomes. Curr Opin Otolaryngol Head Neck Surg 2018; 26 (02) 122-126
    CrossrefPubMedGoogle Scholar